بررسی رابطه درمان ترومبولیتیک در سطح اریتروپویتین پلاسما در انفارکتوس حاد میوکارد

Background and purpose: Myocardial Infraction (MI) is one of the most common diseases in industrial countries. In clinical findings, erythropoietin has shown protection against cellular hypoxic ischemic injury in myocardium. This study assessed the role of erythropoietin in patients with acute MI. Materials and methods: In this cohort study 70 patients with STEMI were divided to two groups: (SK+) that received streptokinase and non-SK (SK-) group. At SK+ group we measured the plasma erythropoietin level before receiving SK, 1hour and three days after receiving SK. In SK- group the level of erythropoietin at entrance to ED, two hours later and on third day was also measured. The relationship between success in reperfusion therapy with ejection fraction and the level of erythropoietin were investigated. Results: The erythropoietin level in those who had successful reperfusion with thrombolytic therapy was significantly higher than those who had not successful reperfusion but no significant relationship was found between ventricular arrhythmias and level of erythropoietin. Ejection fraction at first day in SK+ group was significantly higher (P=0.001). We also observed a significant relationship between plasma erythropoietin level and ejection fraction in both SK + and SK- groups (p=0.001). Conclusion: There are direct relationships between higher level of erythropoietin and success in thrombolytic therapy and also with improvement of EF after AMI.